According to the survival analyses, the median survival time of GC patients with lower expression of MYLK, MYL9, LUM, and CAV1 was1.37, 1.41, 1.35, and 1.42 years; with higher expression of MYLK, MYL9, LUM, and CAV1, the median survival time was 1.06, 1.08, 1.15, and 1.06 years in TCGA database, respectively. Here, MYL9 is linked to gastric cancer.